Senti Biosciences is a clinical-stage biotech developing off-the-shelf CAR-NK (chimeric antigen receptor natural killer) cell therapies for cancer. Senti's core innovation is its proprietary "gene circuit" platform — engineered DNA sequences that program cell therapies with biological logic to sense their environment and respond in programmed ways. This goes beyond conventional single-target CAR therapies by enabling cells to simultaneously process multiple signals. Key gene circuit types include Logic Gates (OR and NOT), Multi-Arming, Regulator Dials, and Smart Sensors. Senti's lead candidate, SENTI-202, is in Phase 1 trials for relapsed/refractory AML (acute myeloid leukemia), a blood cancer with poor prognosis and high unmet need. SENTI-202 combines an OR Gate CAR that targets CD33 and/or FLT3 on cancer cells with a NOT Gate iCAR that spares healthy bone marrow stem cells expressing EMCN — addressing a key challenge that has historically prevented CAR therapies from working in AML. SENTI-202 holds both FDA Orphan Drug and RMAT designations. Senti has no approved products and generates no product revenue. It funds operations through capital raises and collaboration payments. Beyond direct product commercialization, Senti licenses its gene circuit platform to partners outside oncology, including an ongoing collaboration with BlueRock Therapeutics (a Bayer subsidiary) in regenerative medicine. Senti sold its manufacturing assets to GeneFab in 2023, shifting to a contract manufacturing model to focus on clinical development. Senti has 39 employees, and its costs are dominated by R&D and clinical trial expenses.